Review
Prostanoids in the pathophysiology of human coronary artery

https://doi.org/10.1016/j.prostaglandins.2017.03.003Get rights and content

Highlights

  • Benefits of aspirin in CABG and COXIBs associated risks suggest that prostanoids are key mediators in coronary homeostasis.

  • TxA2, PGE2 and PGF induce contraction while PGI2 is responsible for vasodilatation in human coronary artery.

  • Inflammatory stimuli induce COX-2 expression associated with an increase of PGE2 or PGI2 levels in human coronary artery.

  • Sex hormones have a protective role in the development of coronary artery diseases in link with prostanoids.

Abstract

Coronary artery disease is one of the leading causes of death in wordwide. There is growing evidence that prostanoids are involved in the physiology and pathophysiology of the human coronary artery by controlling vascular tone, remodelling of the vascular wall or angiogenesis. In this review, the production of prostanoids and the expression of prostanoid receptors in human coronary artery in health or disease are described. In addition, the interactions between sex hormones and prostanoids, their participations in the development of coronary artery diseases have been addressed. Globally, most of the studies performed in human coronary artery preparations have shown that prostacyclin (PGI2) has beneficial effects by inducing vasodilatation and promoting angiogenesis while reverse effects are confirmed by thromboxane A2 (TxA2). More studies are needed to determine the roles of the other prostanoids (PGE2, PGD2 and PGF) in vascular functions of the human coronary artery. Finally, in addition to the in vitro data about the human coronary artery, myocardial infarction induced by cyclooxygenase-2 (COX-2) inhibitor and the protective effects of aspirin after coronary artery bypass surgery suggest that prostanoids are key mediators in coronary homeostasis.

Introduction

Coronary arteries play a critical role in the supply of blood flow to the myocardium. When the plaque builds up inside the coronary artery, blood flow is partially or totally blocked. This change is named by atherosclerosis and it is the main common reason for coronary artery disease (CAD). This disease has severe implications by decreasing the supply of oxygen and nutrients to the myocardium and may result in myocardial infarction [1]. Several endogenous factors are implicated in the development or progression of CAD, among them prostanoids could be important key elements because of their substantial involvements in the physiology and pathophysiology of the coronary artery.

Prostanoid synthesis is initiated by arachidonic acid release from phospholipids by the action of phospholipase A2 (PLA2) enzymes in the cell membrane. Then arachidonic acid is converted to prostaglandin (PG)H2 via cyclooxygenases (COX-1 and COX-2) enzymes. PGE2, prostacyclin (PGI2), PGD2, PGF and thromboxane A2 (TxA2) are formed from PGH2 via prostanoid synthase enzymes. The prostanoids are involved in vascular homeostasis by regulating vascular wall remodelling and muscular tone [2], [3]. Basically, the vascular wall produces mainly the vasodilator and antiplatelet prostanoid PGI2, while blood components such as platelets release the vasoconstrictor and proaggregant prostanoid TxA2. However, increasing evidences demonstrate synthesis and roles for PGE2 in the cardiovascular system [3], [4]. Interactions between the vascular wall and blood cells could be maintained by the balance between detrimental and beneficial prostanoids in physiological conditions [5]. However, this balance in prostanoid release is impaired in pathophysiological conditions such as CAD. For this reason, the prostanoids could have important impacts on the prevention or treatment of CAD. In fact, emerging evidence on the impact of the prostanoids in coronary artery physiology is strongly suggested by numerous clinical studies concerning both the beneficial effects of aspirin administration in the post-operative period of coronary artery bypass grafting (CABG) surgery [6] and the cardiovascular side effects (such as myocardial infarction) induced by COX-2 inhibitors or NSAIDs (non-steroidal anti-inflammatory drugs) [7]. In this review, we focused on the role of prostanoids in the regulation of human coronary artery homeostasis (vascular tone and wall remodelling) and their involvements in the development of CAD are addressed.

Section snippets

In healthy condition

In normal conditions without inflammatory stimuli, only COX-1 is detectable by western blot and/or RT-PCR analysis in cultured human coronary artery endothelial cells (HCAEC) [8], [9] or smooth muscle cells (HCASMC) [10], [11]. Respective synthase enzymes for PGI2, TxA2 or PGE2 have been detected in HCAEC [9]. In addition, in isolated fresh human coronary artery, the production of all major prostanoids (PGI2, TxA2, PGD2, PGF, PGE2, PGE1) has been confirmed by radioimmunoassay [12].

Regulation of vascular tone by prostanoids in vitro

Prostanoids are implicated in the regulation of human vascular tone by activating their specific receptors. When these receptors are localized on the smooth muscle, classically the activation of IP, EP2, EP4 or DP receptors by prostanoids induces vasodilatation, while the activation of TP, EP1, EP3, or FP receptors is responsible for vasoconstriction [2]. Control of vascular tone by prostanoids in human coronary artery could be differently regulated depending on the stimulus (agonist, hypoxia,

Prostanoids in coronary artery disease

Alterations of prostanoid productions and their synthase enzymes in CAD or related conditions are summarised in Table 2. In vitro expression of COX-2 has been detected in smooth muscle and endothelial cells of atherosclerotic human coronary artery [66], [67]. In addition, during myocardial ischemia, COX-2 mRNA and protein expressions have increased while COX-1 and PGIS levels remain unchanged in human coronary arterioles [68]. Similar results have been obtained by in vivo studies showing that

Conclusions

The mechanism underlying coronary artery diseases is dependent on the interactions between blood cells and coronary artery vascular wall. The roles of prostanoids on platelet aggregation/thrombosis and consequently their involvements in CAD are widely documented in literature. However, there is limited data concerning the effects of prostanoids on the coronary artery vascular wall and most of them were derived from animal studies. The studies performed in human coronary artery preparations

References (144)

  • P. Ganz et al.

    Effects of prostacyclin on coronary hemodynamics at rest and in response to cold pressor testing in patients with angina pectoris

    Am. J. Cardiol.

    (1984)
  • N. Kieler-Jensen et al.

    Effects of prostacyclin on myocardial hemodynamics and metabolism after coronary artery bypass grafting

    J. Cardiothorac. Vasc. Anesth.

    (1996)
  • B.G. Firth et al.

    Hemodynamic effects of intravenous prostacyclin in stable angina pectoris

    Am. J. Cardiol.

    (1983)
  • G.G. Neri Serneri et al.

    Physiologic role of coronary PGI2 and PGE2 in modulating coronary vascular response to sympathetic stimulation

    Am. Heart. J.

    (1990)
  • M.B. Forman et al.

    Effects of indomethacin on systemic and coronary hemodynamics in patients with coronary artery disease

    Am. Heart J.

    (1985)
  • I. Pacold et al.

    Effects of indomethacin on coronary hemodynamics, myocardial metabolism and anginal threshold in coronary artery disease

    Am. J. Cardiol.

    (1986)
  • J.L. Martin et al.

    Effect of high dose aspirin on coronary hemodynamics during pacing-induced myocardial ischemia

    J. Am. Coll. Cardiol.

    (1985)
  • R. Jouve et al.

    Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy

    Am. Heart J.

    (1984)
  • M.H. Petri et al.

    Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells

    Biochem. Biophys. Res. Commun.

    (2013)
  • K. Ishimaru et al.

    Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart

    J. Thorac. Cardiovasc. Surg.

    (2013)
  • Y. Asada et al.

    Inhibitory effects of prostacyclin analogue, TFC-132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro

    Prostaglandins Leukot. Essent. Fatty. Acids

    (1994)
  • J. Feng et al.

    Endothelin-1-induced contractile responses of human coronary arterioles via endothelin-A receptors and PKC-alpha signaling pathways

    Surgery

    (2010)
  • L.D. Hillis et al.

    2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

    J. Thorac. Cardiovasc. Surg.

    (2012)
  • H. Wu et al.

    Preoperative continuation of aspirin therapy may improve perioperative saphenous venous graft patency after off-pump coronary artery bypass grafting

    Ann. Thorac. Surg.

    (2015)
  • G.J. Roth et al.

    Aspirin, platelets, and thrombosis: theory and practice

    Blood

    (1994)
  • F. Lenfant et al.

    Timing of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed

    Maturitas

    (2011)
  • T.H. Jones

    Testosterone deficiency: a risk factor for cardiovascular disease

    Trends. Endocrinol. Metab.

    (2010)
  • G.K. Hansson

    Inflammation, atherosclerosis, and coronary artery disease

    N. Engl. J. Med.

    (2005)
  • X. Norel

    Prostanoid receptors in the human vascular wall

    Sci. World J.

    (2007)
  • B.B. Weksler

    Prostanoids and NSAIDs in cardiovascular biology and disease

    Curr. Atheroscler. Rep.

    (2015)
  • T.P. Gavaghan et al.

    Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study

    Circulation

    (1991)
  • P. McGettigan et al.

    Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries

    PLoS Med.

    (2013)
  • Q. Jiao et al.

    Effect of inflammatory factor-induced cyclo-oxygenase expression on the development of reperfusion-related no-reflow phenomenon in acute myocardial infarction

    Clin. Exp. Pharmacol. Physiol.

    (2015)
  • T. He et al.

    Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells

    Circ. Res.

    (2008)
  • K.L. Osterlund et al.

    Dihydrotestosterone alters cyclooxygenase-2 levels in human coronary artery smooth muscle cells

    Am. J. Physiol. Endocrinol. Metab.

    (2010)
  • A. Virdis et al.

    Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition

    Eur. Heart J.

    (2012)
  • A. Maassen VanDenBrink et al.

    Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane

    Br. J. Pharmacol.

    (1996)
  • K.B. Chow et al.

    Anti-inflammatory activity of ghrelin in human carotid artery cells

    Inflammation

    (2009)
  • M. Kajimoto et al.

    Enhancement of activated beta1-integrin expression by prostaglandin E2 via EP receptors in isolated human coronary arterial endothelial cells: implication for the treatment of Kawasaki disease

    Inflamm. Res.

    (2009)
  • V.V. Raveendran et al.

    Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells

    Immunology

    (2011)
  • X. Tan et al.

    Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I(2) and E(2) production in human coronary artery endothelial cells

    J. Immunol.

    (2007)
  • K. Lakota et al.

    Increased responsiveness of human coronary artery endothelial cells in inflammation and coagulation

    Mediators. Inflamm.

    (2009)
  • B. Callaghan et al.

    Novel and conventional receptors for ghrelin, desacyl-ghrelin, and pharmacologically related compounds

    Pharmacol. Rev.

    (2014)
  • S.K. Venugopal et al.

    C-reactive protein decreases prostacyclin release from human aortic endothelial cells

    Circulation

    (2003)
  • T. Szerafin et al.

    Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus

    Circ. Res.

    (2006)
  • N. Foudi et al.

    Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation

    Cardiovasc. Res.

    (2009)
  • D. Bishop-Bailey et al.

    Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery

    Arterioscler. Thromb. Vasc. Biol.

    (1997)
  • H. Miura et al.

    Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels

    Circ. Res.

    (2003)
  • N. Toda et al.

    Comparison of hypoxia-induced contraction in human, monkey, and dog coronary arteries

    Am. J. Physiol.

    (1992)
  • S.M. Bode et al.

    Chemotactic peptide FMLP contracts human coronary arteries via cyclooxygenase products

    Am. J. Physiol.

    (1990)
  • Cited by (0)

    View full text